Alpha-lipoic acid review reports milder diabetic neuropathy symptoms
Symptom scores improved, while selected nerve measurements and a blood sugar marker showed no significant change.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Alpha-lipoic acid may ease symptoms in people with diabetic neuropathy, according to this review. Tingling, numbness, and pain-related scores improved. Selected nerve measurements and a blood sugar marker did not change significantly, so the findings do not establish nerve recovery or better blood sugar control. The abstract does not show how long improvements lasted.
This abstract-based assessment lacks follow-up lengths, participant totals, and detailed adverse-event results, limiting judgments about durability and safety.
What researchers found
Standardized mean difference in tingling score (TSS paresthesia)
Alpha-lipoic acid versus placebo or other treatments; 95% CI -1.24 to -0.84. This uses standard-deviation units, which account for score variability, rather than raw points or percentages. Negative values mean milder tingling. Follow-up: not reported in the abstract.
What was compared
The review combined studies of symptoms, laboratory markers, and function. Different doses were represented, but the abstract does not establish that one dose outperformed another in direct comparisons.
Uncertainty beyond symptoms
Selected nerve measurements, HbA1c, and nitric oxide did not change significantly. This leaves uncertainty about effects beyond symptoms; a nonsignificant result does not prove there was no effect.
The original publication
Effectiveness of alpha lipoic acid supplementation on biochemical, clinical, and inflammatory parameters in patients with diabetic polyneuropathy: A systematic review and meta-analysis.
Salinas AV, Caroca TM, Santibáñez FP et al.
Diabetes Metab Syndr · 2026
- PubMed ID
- 41619689
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.